Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Mutant p53 (Mt p53) abrogates tumor suppression and causes chemoresistance via gain-of-function effects.
• Mt p53's dominant-negative impact stems from aggregation, leading to wild-type p53 (WT p53) co-aggregation.
• Hypoxia influences WT p53 conformation, potentially contributing to p53 inactivation in tumors.

Purpose of the Study:

• To investigate the mechanism of p53 inactivation in hypoxic conditions.
• To determine if WT p53 can rescue Mt p53 within hypoxic tumors.
• To explore WT p53's potential as a molecular chaperone therapy for cancer.

Main Methods:

• In vivo chaperone assays were employed to assess WT p53's rescue capabilities.
• Analysis of WT p53 conformation under simulated hypoxia in cell cultures.
• Tumor xenograft models were used to evaluate the therapeutic efficacy of WT p53 chaperone therapy.

Main Results:

• WT p53 functions as a molecular chaperone, rescuing conformational and structural p53 mutants at transcriptional and proteomic levels.
• WT p53 chaperone therapy significantly regressed tumor xenografts by converting the mutant phenotype to WT p53.
• The chaperone function of WT p53 was directly linked to the induction of apoptosis in cancer cells and tumors.

Conclusions:

• WT p53 possesses intrinsic chaperone activity that can counteract the effects of oncogenic p53 mutants, particularly in hypoxic tumor environments.
• WT p53 chaperone therapy represents a promising novel therapeutic strategy for chemoresistant hypoxic tumors.
• This approach offers new dimensions to existing cancer therapeutics by targeting p53 dysfunction.